50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
One Stock Doubles Your Money, During Crisis? (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
German leader seeks energy deals, alliances on Gulf trip
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
5 Monthly Dividends Yielding 7.9% to 18.3%
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Poverty, inflation, fear: Egypt's economy pushed to brink
Poverty and inflation: Egypt's economy hit by global turmoil
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
One Stock Doubles Your Money, During Crisis? (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
German leader seeks energy deals, alliances on Gulf trip
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
5 Monthly Dividends Yielding 7.9% to 18.3%
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Poverty, inflation, fear: Egypt's economy pushed to brink
Poverty and inflation: Egypt's economy hit by global turmoil
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
One Stock Doubles Your Money, During Crisis? (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
German leader seeks energy deals, alliances on Gulf trip
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
5 Monthly Dividends Yielding 7.9% to 18.3%
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Poverty, inflation, fear: Egypt's economy pushed to brink
Poverty and inflation: Egypt's economy hit by global turmoil
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
One Stock Doubles Your Money, During Crisis? (Ad)
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
German leader seeks energy deals, alliances on Gulf trip
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Saudi Arabia's triumphant week reclaims the West's embrace
5 Monthly Dividends Yielding 7.9% to 18.3%
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Poverty, inflation, fear: Egypt's economy pushed to brink
Poverty and inflation: Egypt's economy hit by global turmoil
NASDAQ:ENTA

Enanta Pharmaceuticals - ENTA Stock Forecast, Price & News

$50.94
-1.71 (-3.25%)
(As of 09/23/2022 12:00 AM ET)
Add
Compare
Today's Range
$49.61
$52.45
50-Day Range
$48.29
$71.27
52-Week Range
$37.59
$102.00
Volume
186,537 shs
Average Volume
228,728 shs
Market Capitalization
$1.06 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$78.63

Enanta Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.63 Rating Score
Upside/​Downside
54.3% Upside
$78.63 Price Target
Short Interest
Bearish
7.66% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.44
Upright™ Environmental Score
News Sentiment
0.76mentions of Enanta Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($5.75) to ($2.99) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.53 out of 5 stars

Medical Sector

157th out of 1,075 stocks

Pharmaceutical Preparations Industry

58th out of 532 stocks

ENTA stock logo

About Enanta Pharmaceuticals (NASDAQ:ENTA) Stock

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

Receive ENTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ENTA Stock News Headlines

What 13 Analyst Ratings Have To Say About Enanta Pharmaceuticals
Enanta Shares Rise On Positive Data From Initial-Stage Covid Study
Enanta Pharmaceuticals Inc - Stock Chart
Analyst Ratings for Enanta Pharmaceuticals
See More Headlines
Receive ENTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ENTA Company Calendar

Last Earnings
8/08/2022
Today
9/25/2022
Fiscal Year End
9/30/2022
Next Earnings (Estimated)
11/28/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ENTA
Employees
155
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$78.63
High Stock Price Forecast
$137.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+54.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
8 Analysts

Profitability

Net Income
$-79,000,000.00
Net Margins
-134.21%
Pretax Margin
-144.58%

Debt

Sales & Book Value

Annual Sales
$97.07 million
Book Value
$19.76 per share

Miscellaneous

Free Float
18,292,000
Market Cap
$1.06 billion
Optionable
Optionable
Beta
0.55

Key Executives

  • Dr. Jay R. LulyDr. Jay R. Luly (Age 66)
    Pres, CEO & Director
    Comp: $1.23M
  • Mr. Paul J. Mellett Jr.Mr. Paul J. Mellett Jr. (Age 67)
    Sr. VP of Fin. & Admin. and CFO
    Comp: $652.39k
  • Dr. Yat Sun Or (Age 70)
    Sr. VP of R&D and Chief Scientific Officer
    Comp: $729.75k
  • Ms. Tara Lynn Kieffer Ph.D. (Age 44)
    Sr. VP of New Product Strategy & Devel.
    Comp: $496.85k
  • Mr. Brendan Luu
    Sr. VP of Bus. Devel.
  • Ms. Jennifer Viera
    Sr. Director of Investor Relations & Corp. Communications
  • Mr. Nathaniel S. Gardiner J.D. (Age 68)
    Sr. VP, Gen. Counsel & Sec.
  • Dr. Nathalie Adda M.D. (Age 56)
    Consultant
  • Dr. Scott T. Rottinghaus
    Sr. VP & Chief Medical Officer













ENTA Stock - Frequently Asked Questions

Should I buy or sell Enanta Pharmaceuticals stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ENTA shares.
View ENTA analyst ratings
or view top-rated stocks.

What is Enanta Pharmaceuticals' stock price forecast for 2022?

8 brokers have issued 1 year price targets for Enanta Pharmaceuticals' shares. Their ENTA share price forecasts range from $50.00 to $137.00. On average, they anticipate the company's stock price to reach $78.63 in the next twelve months. This suggests a possible upside of 54.3% from the stock's current price.
View analysts price targets for ENTA
or view top-rated stocks among Wall Street analysts.

How have ENTA shares performed in 2022?

Enanta Pharmaceuticals' stock was trading at $74.78 at the beginning of the year. Since then, ENTA stock has decreased by 31.9% and is now trading at $50.94.
View the best growth stocks for 2022 here
.

When is Enanta Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 28th 2022.
View our ENTA earnings forecast
.

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) released its quarterly earnings data on Monday, August, 8th. The biotechnology company reported ($1.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.36) by $0.17. The biotechnology company earned $19.48 million during the quarter, compared to analyst estimates of $20.73 million. Enanta Pharmaceuticals had a negative net margin of 134.21% and a negative trailing twelve-month return on equity of 32.42%. The company's revenue was down 9.9% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.19) EPS.

What is Jay R. Luly's approval rating as Enanta Pharmaceuticals' CEO?

5 employees have rated Enanta Pharmaceuticals Chief Executive Officer Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among the company's employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Enanta Pharmaceuticals to a friend.

What other stocks do shareholders of Enanta Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS).

What is Enanta Pharmaceuticals' stock symbol?

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Who are Enanta Pharmaceuticals' major shareholders?

Enanta Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include State Street Corp (8.20%), Northern Trust Corp (4.49%), Renaissance Technologies LLC (2.62%), FMR LLC (1.69%), Price T Rowe Associates Inc. MD (0.91%) and JPMorgan Chase & Co. (0.86%). Insiders that own company stock include Bruce L A Carter, Jay R Luly, Nathalie Adda and Paul J Mellett.
View institutional ownership trends
.

How do I buy shares of Enanta Pharmaceuticals?

Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enanta Pharmaceuticals' stock price today?

One share of ENTA stock can currently be purchased for approximately $50.94.

How much money does Enanta Pharmaceuticals make?

Enanta Pharmaceuticals (NASDAQ:ENTA) has a market capitalization of $1.06 billion and generates $97.07 million in revenue each year. The biotechnology company earns $-79,000,000.00 in net income (profit) each year or ($5.86) on an earnings per share basis.

How many employees does Enanta Pharmaceuticals have?

The company employs 155 workers across the globe.

How can I contact Enanta Pharmaceuticals?

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The official website for the company is www.enanta.com. The biotechnology company can be reached via phone at (617) 607-0800, via email at cmiceli@enanta.com, or via fax at 617-607-0530.

This page (NASDAQ:ENTA) was last updated on 9/25/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.